Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific (BSX) to $129 from $125 and keeps a Buy rating on the shares. The firm is bullish on the company’s long-term growth prospects after its Investor Day presentation, the analyst tells investors in a research note. Boston Scientific continues to stand out as a top performing large-cap MedTech with a best-in-class pipeline and attractive end-markets sustaining above-average double-digit revenue and EPS growth, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Elutia closes sale of its BioEnvelope business to Boston Scientific for $88M
- Boston Scientific price target raised to $132 from $127 at BTIG
- Boston Scientific price target raised to $128 from $123 at Baird
- Boston Scientific price target raised to $132 from $131 at Canaccord
- Boston Scientific’s Strong Growth Potential and Strategic Positioning Justify Buy Rating